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Background: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the
United States. Long-acting muscarinic antagonists (LAMAs) are a class of medications used as mainte-
nance therapy for COPD. The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study
assessed the long-term safety and efﬁcacy of a LAMA, glycopyrrolate (GLY) 15.6 mg twice daily (b.i.d.),
compared with an approved long-acting b2-agonist (LABA), indacaterol (IND) 75 mg once daily (q.d.) in
patients with stable, symptomatic COPD with moderate-to-severe airﬂow limitation.
Methods: This 52-week, multicenter, double-blind, parallel-group study randomized patients (1:1) of the
United States to receive GLY 15.6 mg b.i.d. or IND 75 mg q.d. both delivered via the Neohaler® device. The
primary objective was to assess the safety and tolerability in terms of adverse event (AE) reporting rates
over 52 weeks. Safety was also determined by evaluating multiple secondary endpoints, including vital
signs, electrocardiograms (ECGs), and time to ﬁrst moderate or severe exacerbation. Efﬁcacy-related
secondary endpoints included pre-dose forced expiratory volume in one second (FEV1) and forced vi-
tal capacity (FVC).
Results: Of the 511 randomized patients (GLY, n ¼ 254; IND, n ¼ 257), 81.6% completed the study. The
overall incidences of AEs (GLY, 77.3%; IND, 77.0%) and serious AEs (GLY, 13.1%; IND, 13.3%) were com-
parable between the groups. The incidence of major adverse cardiovascular events was low and com-
parable between the groups. No clinically relevant differences for vital signs or ECG parameters were
observed between the treatment groups. The three sudden deaths reported within 30 days of the
treatment (GLY, n ¼ 2; IND, n ¼ 1) were adjudicated as unrelated to the study medication. In terms of
efﬁcacy, GLY 15.6 mg b.i.d. showed improvements in pre-dose FEV1 and FVC from baseline, which was
comparable to those with IND 75 mg q.d., with no statistically signiﬁcant differences. No signiﬁcant
differences were observed between the treatment groups in the time to ﬁrst moderate or severe COPD
exacerbation.
Conclusion: GLY 15.6 mg b.i.d. showed a long-term safety proﬁle comparable to that of IND 75 mg q.d. and
provided rapid and sustained bronchodilation over 52 weeks in patients with COPD with moderate-to-
severe airﬂow limitation.
Clinical trial registration number: NCT01697696.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).at Dartmouth, Hanover, NH
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Chronic obstructive pulmonary disease (COPD) is a progressive
lung disease which remains one of the leading causes of death and




CCV cardiovascular and cerebrovascular
CI conﬁdence interval
COPD chronic obstructive pulmonary disease
ECG electrocardiogram
FAS full analysis set
FEV1 forced expiratory volume in one second
FVC forced vital capacity
GEM Glycopyrrolate Effect on syMptoms and lung function
GLY glycopyrrolate




LAMA long-acting muscarinic antagonist
LSM least squares mean
MACE major adverse cardiovascular events
mMRC modiﬁed Medical Research Council
MMRM mixed model repeated measures
OR odds ratio
q.d. once daily
SAE serious adverse event;
SD standard deviation
D.A. Mahler et al. / Respiratory Medicine 115 (2016) 39e4540with speciﬁc comorbidities, which overall leads to an increase in
healthcare utilization and costs [1,2]. Although there is no cure for
this disease, several pharmacological therapies exist which can
help relieve the associated symptoms [3]. The current Global
Initiative for Chronic Obstructive Lung Disease (GOLD) [3] guide-
lines and the American Thoracic Society/European Respiratory So-
ciety guidelines [4] recommend treatment of COPD with long-
acting bronchodilators such as long-acting muscarinic antagonists
(LAMAs) and long-acting b2-agonists (LABAs) alone or in a ﬁxed
dose combination or in combination with an inhaled corticosteroid
(ICS).
Glycopyrrolate (GLY), also known as glycopyrronium bromide,
administered as a 63 mg once-daily (q.d.) dose (equivalent to gly-
copyrronium 50 mg), is a fast-onset LAMA which provides a sus-
tained 24-h bronchodilation in patients with moderate-to-severe
COPD [5,6]. Inhaled glycopyrronium 50 mg q.d. (Seebri®
Breezhaler®) has been approved as a maintenance bronchodilator
for symptomatic treatment of patients with COPD in more than 80
countries, including countries within the EU and Latin America,
Japan, Canada, Switzerland, and Australia [7]. Results from Phase III
trials have shown that glycopyrronium 50 mg q.d. offers a sub-
stantial beneﬁt to patients with moderate-to-severe COPD by
improving lung function, decreasing dyspnea, improving health
status, and decreasing rescue medication use, along with an overall
acceptable safety proﬁle [8]. Glycopyrronium 50 mg q.d. has also
demonstrated an efﬁcacy and safety proﬁle comparable to that of
tiotropium 18 mg q.d. [9,10]. Moreover, a comprehensive safety
analysis using the pooled data from six clinical studies and a post-
marketing surveillance exhibited a comparable safety proﬁle for
glycopyrronium 50 mg q.d. to those of tiotropium and placebo [11].
A dose-ranging study revealed that GLY 15.6 mg (equivalent to
glycopyrronium 12.5 mg) twice daily (b.i.d.) resulted in statistically
signiﬁcant and clinically relevant improvements in trough forced
expiratory volume in one second (FEV1). Based on these data and
discussions with the Food and Drug Administration, GLY
15.6 mg b.i.d. delivered via the low-resistance Neohaler® device was
selected for the US Phase III clinical program [12]. This program
included two replicate 12-week studies (GEM1, GEM2) and a 52-
week long-term study, GEM3 (Glycopyrrolate Effect on syMptoms
and lung function). The GEM1 and GEM2 studies supported the
efﬁcacy and safety of GLY 15.6 mg b.i.d. showing improvements in
lung function, COPD symptoms, health status, and rescue medica-
tion use, with a safety proﬁle comparable to that of placebo [13,14].
GLY is now approved at a 15.6 mg b.i.d. dose (Seebri™ Neohaler®) in
the US, for the long-term maintenance treatment of airﬂow
obstruction in patients with COPD, including chronic bronchitis
and/or emphysema [15].Here we report the results from the GEM3 study which evalu-
ated the long-term safety and efﬁcacy of GLY 15.6 mg b.i.d. over 52
weeks using an approved LABA, indacaterol (IND) 75 mg q.d., as a
control, in a patient population in the US, with stable, symptomatic
COPD with moderate-to-severe airﬂow limitation (according to the
GOLD 2011 guidelines).2. Methods
2.1. Study design and treatment
GEM3 was a 52-week, randomized, multicenter, double-blind,
parallel-group study conducted at 65 centers in the US (Clinical-
Trials.gov registration number: NCT01697696). The study
comprised of a ﬂexible screening period (between 1 and 7 days), a
two-week run-in period, a 52-week randomized treatment period,
and a 30-day safety follow-up period (Fig. 1). During the screening
and run-in periods, several prohibited concomitant medications,
such as LABAs, LAMAs and xanthines, had to be discontinued, and a
stable background treatment with ICS was permitted to be
continued throughout the study. During the study, patients were
provided with albuterol as a rescue medication. At the start of the
run-in period, patients were provided with an electronic patient
diary (eDiary) to record symptoms and rescue medication usage
twice daily. At the end of the run-in period, eligible patients were
randomized (1:1) to receive GLY 15.6 mg b.i.d. (morning and eve-
ning dosing) or IND 75 mg q.d. (morning dosing), both delivered via
a low-resistance, single-dose, dry powder inhaler (Neohaler™ de-
vice) for 52 weeks. The IND group received a matching placebo in
the evening to maintain blinding. All randomized patients,
regardless of whether they completed or discontinued the treat-
ment before Week 52, were monitored throughout the treatment
period and in the subsequent follow-up period (Fig. 1). The ﬁrst
patient was enrolled on October 26, 2012, and the last patient visit
was completed on November 13, 2014. Additional details of the
randomization and blinding procedures are included in the online
supplementary material. This study was approved by the institu-
tional review board for each center and was conducted in accor-
dance with the ethical principles of the Declaration of Helsinki. All
patients provided written informed consent before participating in
the study.2.2. Patients
The study population included male and female patients aged
40 years with stable COPD (GOLD 2011 levels 2 and 3), who were
current or ex-smokers with a smoking history of at least 10 pack-
Fig. 1. Study design. *Screening epoch was kept ﬂexible between 1 and 7 days. b.i.d., twice daily; q.d., once daily.
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<80% of the predicted normal, and a post-bronchodilator FEV1/
forced vital capacity (FVC) < 0.70, and with a modiﬁed Medical
Research Council (mMRC) Dyspnea Scale grade of at least 2 at the
run-in visit. Key exclusion criteria included history of long QT
syndrome or patients whose Fridericia corrected QT interval (QTcF)
measured at the run-in visit was prolonged (>450 ms), clinically
signiﬁcant electrocardiogram (ECG) abnormality before randomi-
zation or at the run-in visit, clinically signiﬁcant cardiovascular
disease including signiﬁcant arrhythmia, renal abnormalities, his-
tory of asthma, and COPD exacerbations that required treatment
with antibiotics and/or systemic corticosteroids and/or hospitali-
zation within the six weeks before the screening or during the
screening and run-in periods. Detailed inclusion and exclusion
criteria are provided in the online supplementary material.2.3. Study objectives
The primary objective was to assess the safety and tolerability of
GLY 15.6 mg b.i.d. over the 52-week treatment period versus IND
75 mg q.d. in terms of the adverse event (AE) reporting rates. Safety-
related secondary endpoints included time to ﬁrst moderate or
severe COPD exacerbations, measurement of vital signs, ECG, and
laboratory evaluations over 52 weeks. Efﬁcacy-related secondary
endpoints included pre-dose trough FEV1 at Week 52 (mean of
FEV1 values at 45 and 15 min before the morning dose), FEV1
and FVCmeasurements at all post-baseline time-points, and rescue
medication use over 52 weeks of treatment period.2.4. Statistical analyses
All statistical analyses described in this and subsequent sections
were performed using the Statistical Analysis Software (SAS)
Version 9.3 (Cary, NC). The primary analysis was the comparison of
the overall AE rates between the treatment groups in terms of
absolute and relative frequencies of treatment emergent AEs by
primary system organ class and preferred term. It was performed
on the safety set, which included all patients who received at least
one dose of the study drug and had at least one post-baseline safety
assessment. Treatment emergent AEs were deﬁned as AEs starting
on or after the time of the ﬁrst administration of the study drug but
not later than 7 days (30 days in case of a serious adverse event
[SAE]) after the last administration. No statistical testing of the
hypothesis was performed.In addition, AEs adjusted for exposure and by major adverse
cardiovascular events (MACE) outcomes were summarized.
The rate of moderate-to-severe COPD exacerbations was
analyzed using a generalized linear model assuming a negative
binomial distribution. The log (exposure time) was used as an offset
variable in the model. The model included treatment, baseline total
symptom score, history of baseline COPD exacerbation (i.e., the
number of COPD exacerbations during the 12 months prior to
study), smoking status at baseline, history of ICS use, and COPD
disease severity as ﬁxed effects. The time to ﬁrst moderate or severe
COPD exacerbation was analyzed using Cox regression model for
the full analysis set (FAS), which included all randomized patients
who received at least one dose of the study drug. The model
included treatment, baseline total symptom score, history of
baseline COPD exacerbation (i.e., the number of COPD exacerba-
tions during 12 months prior to study), smoking status at baseline,
history of ICS use, and COPD disease severity as ﬁxed effects. All
safety assessments were performed on the safety set.
Efﬁcacy endpoints were evaluated as secondary parameters on
the FAS. The change from baseline in the pre-dose trough FEV1 (L)
(average of the two FEV1 (L) measurements 45 and 15 min pre-
dose) at all post-baseline visits was analyzed using a mixed-
model repeated-measures (MMRM) analysis on the FAS. The
model contained treatment, baseline FEV1, visit, treatment by visit
interaction, visit by baseline FEV1 interaction, smoking status at
baseline, history of ICS use, and COPD disease severity as ﬁxed ef-
fects with an unstructured variance-covariance error matrix. The
number of puffs of rescue medication was recorded twice daily by
the patient in an electronic diary (eDiary) provided at the start of
run-in period. Patient classiﬁcation and sample size calculation are
provided in the online supplementary material.3. Results
3.1. Patient disposition and baseline characteristics
Of the 1296 screened patients, 511 were randomized to either
the GLY (n ¼ 254) or the IND (n ¼ 257) group. A total of 417 (81.6%)
(GLY, n ¼ 207; IND, n ¼ 210) patients completed the 52-week
planned treatment period (Fig. 2); this included patients who
completed the 52-week treatment period (66.1%) as well as those
who discontinued the study treatment but continued study visits as
part of the planned treatment period (15.5% of the total popula-
tion). The most common reason for discontinuation was patient
D.A. Mahler et al. / Respiratory Medicine 115 (2016) 39e4542decision, with similar rates between both the treatment groups
(Fig. 2).
The safety set included 507 patients. Of these, 33.9% of patients
permanently discontinued the study treatment before the end of
the planned treatment period, with discontinuation rates compa-
rable between both treatment groups (Table A.1). The mean
(standard deviation [SD]) duration of exposure was comparable
between both the treatment groups (GLY, 290.3 [119.05] days; IND,
285.0 [126.18] days).
Patient demographics and baseline characteristics were com-
parable between both treatment groups (Table 1). A majority of the
patients were Caucasian (90.9%) and with moderate airﬂow limi-
tation (54.0%). Most of the patients belonged to GOLD 2011 Group B
(51.5%), followed by Group D (45.0%), and a majority (74.2%) did not
have COPD exacerbations in the year prior to the study entry
(Table 1).3.2. Safety
3.2.1. Adverse events
Overall, the incidence of AEs was comparable between the GLY
(77.3%) and IND (77.0%) groups (Table 2). A majority of AEs reported
in both the treatment groups were mild (20.3%) or moderate
(43.4%) in severity and occurred at comparable rates. AEs by
preferred termwere predominantly respiratory-related, with COPD
(exacerbation) as the most commonly reported AE, which occurred
at comparable rates between the treatment groups (GLY, 36.3%;
IND, 37.1%). Moreover, COPD (exacerbations) was the primary
reason of study drug discontinuation (GLY, 3.6%; IND, 2.0%). Severe
AEs were reported in 13.9% of patients in the GLY group compared
with 12.9% in the IND group. The incidence of suspected drug-
related AEs was low and comparable between both the groups
(GLY, 12.4%; IND, 9.0%). The rate of AEs reported to have led to
permanent discontinuation from the study was low in both theFig. 2. Patient disposition. *One patient was erroneously randomized to IND group. #Two d
30 days after the last dose of study medication. yOne site was prematurely closed due to
glycopyrrolate; IND, indacaterol; q.d., once daily.treatment groups (GLY, 8.8%; IND, 9.8%).
3.2.2. Serious adverse events (SAEs) and deaths
Overall, the incidence of SAEs was balanced between the groups
(GLY, 13.1%; IND, 13.3%). Most of the SAEs were respiratory-related,
and the incidence rate was comparable between the treatments
(GLY, 4.8%; IND, 5.5%). COPD exacerbation was the most frequently
reported SAE, with similar rates between GLY (4.4%) and IND (4.7%).
The rate of discontinuations of the study medication due to SAEs
was low and comparable between the treatments (GLY, 4.0%; IND,
4.7%). Three deaths due to AEs were reported while on the study
medication or within 30 days of the last study medication intake
(GLY, n ¼ 2; IND, n ¼ 1).The adjudicated cause of deaths in both the
groups was sudden death. None of the patients had a history of
atrial ﬁbrillation/ﬂutter or cardiac arrhythmia and all patients had
baseline cardiovascular risk factors. Moreover, no death was
considered related to the study medication by the investigator.
3.2.3. Cardiovascular and cerebrovascular events
The incidence of serious cardiovascular and cerebrovascular
(CCV) AEs was similar between the treatments (GLY, 3.2%; IND,
3.1%). Serious CCV events were evaluated by an independent
adjudication committee and were adjudicated for MACE or non-
MACE outcome. Similarly, all cases of atrial ﬁbrillation/atrial
ﬂutter that occurred between randomization and the end of the
follow-up period were adjudicated as new-onset or recurrent
events. Adjudicated serious CCV AEs were comparable, with similar
incidence rates of MACE and non-MACE in the two treatment
groups (Table 3). The time to ﬁrst serious CCV events adjudicated by
MACE outcome was similar in the treatment groups. No discernible
pattern was observed in subgroup analyses of serious CCV AEs
adjudicated by MACE outcome (Table A.2).
The incidences of cardiac arrhythmias (GLY, 1.6%; IND, 3.1%),
cardiac failure (GLY, 0.0%; IND, 0.8%) and cerebrovascular eventseaths in the GLY 15.6 mg b.i.d. group and one death in the IND 75 mg q.d. group occurred
critical GCP non-compliance issues. b.i.d., twice daily; GCP, Good Clinical Practice; GLY,
Table 1
Patient demographics and baseline characteristics (Safety set).
Parameters GLY 15.6 mg b.i.d.
n ¼ 251
IND 75 mg q.d.
n ¼ 256
Age (years) 63.3 (9.15) 63.2 (8.91)
Male, n (%) 141 (56.2) 149 (58.2)
Female, n (%) 110 (43.8) 107 (41.8)
Race, n (%)
Caucasian 230 (91.6) 231 (90.2)
Black 17 (6.8) 19 (7.4)
Others 4 (1.6) 6 (2.34)
Duration of COPD (years) 7.0 (5.65) 6.6 (5.97)
Smoking history, n (%)
Ex-smoker 115 (45.8) 114 (44.5)
Current smoker 136 (54.2) 142 (55.5)
Number of pack-years 48.6 (25.92) 54.2 (26.38)
Severity of COPD, airﬂow limitation, n (%)
Moderate (GOLD 2) 133 (53.0) 141 (55.1)
Severe (GOLD 3) 110 (43.8) 104 (40.6)
Very severe (GOLD 4) 0 1 (0.4)
Missing 8 (3.2) 10 (3.9)
Severity of COPD, combined assessment, n (%)
Group B 126 (50.2) 135 (52.7)
Group C 0 1 (0.4)
Group D 117 (46.6) 111 (43.4)
Missing 8 (3.2) 9 (3.5)
COPD exacerbation history, n (%)
0 192 (76.5) 184 (71.9)
1 43 (17.1) 59 (23.0)
2 16 (6.4) 13 (5.1)
ICS use at baseline, n (%) 93 (37.1) 92 (35.9)
mMRC dyspnea scale, n (%)
Grade 1 0 1 (0.4)
Grade 2 158 (62.9) 151 (59.0)
Grade 3 79 (31.5) 91 (35.5)
Grade 4 14 (5.6) 13 (5.1)
COPD assessment test (CAT) score 18.3 (7.53) 18.2 (7.61)
Pre-bronchodilator FEV1 (L) 1.24 (0.50) 1.25 (0.46)
Post-bronchodilator FEV1 (L) 1.46 (0.53) 1.47 (0.49)
Post-bronchodilator FEV1, % predicted 53.1 (14.01) 53.1 (12.94)
Post-bronchodilator FEV1 reversibility, %a 21.2 (16.51) 21.1 (15.30)
Cardiovascular risk factors
CCV history/condition 66 (26.3) 48 (18.8)
Hypertension 142 (56.6) 150 (58.6)
Diabetes mellitus 51 (20.3) 30 (11.7)
Atrial ﬁbrillation/ﬂutter 4 (1.6) 2 (0.8)
Hyperlipidemia 145 (57.8) 146 (57.0)
Data is presented as mean (standard deviation) unless otherwise stated. aFEV1
reversibility is calculated as percentage increase of FEV1 value after inhalation of
bronchodilator relative to FEV1 value before inhalation. COPD severity is based on
the GOLD 2011 criteria. b.i.d., twice daily; q.d., once daily; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in one second; GOLD, Global
Initiative for Chronic Obstructive Lung Disease; GLY, glycopyrrolate; IND, indaca-
terol; ICS, inhaled corticosteroid; mMRC, modiﬁed Medical Research Council; CCV,
cardiovascular and cerebrovascular; pack-years, total years of smoking  cigarette
packs smoked/day.
Table 2
Frequent AEs (3% of patients in either treatment group) by preferred term (Safety
set).
Preferred term GLY 15.6 mg b.i.d.
n ¼ 251
IND 75 mg q.d.
n ¼ 256
Patients with at least one AE 194 (77.3) 197 (77.0)
COPD* 91 (36.3) 95 (37.1)
Nasopharyngitis 20 (8.0) 27 (10.5)
Cough 18 (7.2) 20 (7.8)
Dyspnea 14 (5.6) 9 (3.5)
Upper respiratory tract infection 14 (5.6) 16 (6.3)
Viral upper respiratory tract infection 12 (4.8) 12 (4.7)
Bronchitis 11 (4.4) 10 (3.9)
Fatigue 11 (4.4) 3 (1.2)
Oropharyngeal pain 11 (4.4) 11 (4.3)
Sinusitis 10 (4.0) 12 (4.7)
Diarrhea 9 (3.6) 5 (2.0)
Nasal congestion 9 (3.6) 9 (3.5)
Nausea 9 (3.6) 6 (2.3)
Back pain 8 (3.2) 4 (1.6)
Urinary tract infection 8 (3.2) 6 (2.3)
Headache 4 (1.6) 8 (3.1)
Hypertension 3 (1.2) 8 (3.1)
Lower respiratory tract infection 3 (1.2) 10 (3.9)
All values presented as n (%). *worsening of COPD which includes COPD exacerba-
tion. b.i.d., twice daily; COPD, chronic obstructive pulmonary disease; AE, adverse
event; GLY, glycopyrrolate; IND, indacaterol; q.d., once daily.
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group. Atrial ﬁbrillation/ﬂutter events occurred in four (1.6%) and
ﬁve (2.0%) patients in the GLY and IND groups, respectively, of
whom, one patient in the GLY group and two in the IND group had
new onset of events.3.2.4. Additional safety parameters
There were no clinically meaningful differences between the
two treatment groups for any of the vital signs (pulse rate and,
systolic and diastolic blood pressure), and hematology, biochem-
istry, or urinalysis parameters. The proportion of patients with
newly occurring or worsening clinically notable QTcF values was
comparable in both the treatment groups. The number of patients
who showed an increase from baseline in QTcF of 30e60 ms was
low and comparable between both the treatment groups (GLY,n ¼ 28 [11.2%]; IND, n ¼ 23 patients [9.0%]). None of these




The change from baseline in the pre-dose trough FEV1 (an
average of the two FEV1 measurements 45 and 15 min pre-dose)
was analyzed at all post-baseline visits; no statistically signiﬁcant
differences were observed between the two treatments at any visit
(Fig. 3, additional data in Table A.4). Similar proﬁles of the least
squares mean (LSM) change from baseline in the pre-dose trough
FEV1 (L) was seen over all visits for both the treatment groups
throughout the entire treatment period (Fig. 3, Additional data in
Table A.4). At the end of the treatment period, the change from
baseline in the pre-dose FEV1 was also comparable between the
groups (GLY, 0.056 L; IND, 0.060 L; treatment difference, 0.004 L,
p ¼ 0.902). Moreover, no statistically signiﬁcant treatment differ-
ences were observed between the treatment groups for pre-dose
trough FVC (change from baseline) at any visit, with the excep-
tion of Week 12, which showed a difference in favor of GLY (LSM
treatment difference, 0.071 L; p ¼ 0.049).
3.3.2. COPD exacerbations
Over 52 weeks of treatment, no statistically signiﬁcant differ-
ences were found between the treatment groups for the incidence
of moderate or severe COPD exacerbations (incidence rate ratio,
0.92; 95% CI: 0.65, 1.29; p ¼ 0.625). The number of moderate or
severe COPD exacerbations over the treatment period is given in
the Table A.3. Moreover, the time to ﬁrst moderate or severe COPD
exacerbation was also comparable across both the treatment
groups (hazard ratio, 0.92; 95% CI: 0.64, 1.31; p ¼ 0.636).
3.3.3. Rescue medication use
There were no statistically signiﬁcant difference between GLY
and IND treatments for the mean nighttime number of puffs of the
rescue medication (treatment difference, 0.21 puffs; p ¼ 0.071) or
the number of days with no rescue medication use (treatment
Table 3
Serious CCV events adjudicated by MACE outcome (Safety set).
Adjudicated MACE outcome GLY 15.6 mg b.i.d.
n ¼ 251
IND 75 mg q.d.
n ¼ 256
Patients with at least one adjudicated serious CCV AE 8 (3.2) 9 (3.5)
MACE* 4 (1.6) 5 (2.0)
Non-fatal myocardial infarction 2 (0.8) 3 (1.2)
Non-fatal unstable angina 0 0
Non-fatal stroke 0 0
Heart failure requiring hospitalization 0 0
Coronary re-vascularization (CABG or PCI) 4 (1.6) 3 (1.2)
Non-MACE serious CCV AE* 5 (2.0) 6 (2.3)
All values are presented as n (%); table includes events that occurred on or after the time of the ﬁrst administration of the study drug but not later than
30 days after the last administration. A patient with multiple events was included for each event. *Patients may have had both MACE and non-MACE,
therefore the values may not be additive.
CCV AE, cardiovascular and cerebrovascular adverse events; MACE, major adverse cardiovascular events; CABG, coronary artery bypass graft; PCI,
percutaneous coronary intervention; GLY, glycopyrrolate; IND, indacaterol; b.i.d., twice daily; q.d., once daily.
Fig. 3. Change in pre-dose trough FEV1 from baseline, over post-baseline visits
(FAS). MMRM: Change from baseline in pre-dose trough FEV1 ¼ treatment þ baseline
FEV1 þ smoking status at baseline þ baseline ICS use þ visit þ treatment by visit
interaction þ visit by baseline FEV1 interaction þ COPD disease severity; Pre-dose
trough FEV1 is deﬁned as the mean of FEV1 at 45 and 15 min before the morning
dose. The number of patients included in the analysis, GLY (n ¼ 229) and IND (n ¼ 227)
at all the assessed time-points. MMRM, mixed model repeated measures; LSM, least
squares mean; FAS, full analysis set; GLY, glycopyrrolate; IND, indacaterol, b.i.d., twice
daily; q.d., once daily; FEV1, forced expiratory volume in one second.
D.A. Mahler et al. / Respiratory Medicine 115 (2016) 39e4544difference, 5.7 days; p ¼ 0.057). However, the change from
baseline in the use of the rescue medication was numerically lower
in daily (treatment difference, 0.63 puffs; p ¼ 0.014), and daytime
(treatment difference, 0.34 puffs; p ¼ 0.014) number of puffs with
IND versus that with GLY.4. Discussion
The overall results of the GEM3 study demonstrate that the
safety and efﬁcacy of GLY b.i.d. were comparable to safety and ef-
ﬁcacy of an approved LABA, IND, in patients with moderate-to-
severe COPD over the 52-week treatment period. IND was chosen
as the active comparator in this study for ethical reasons regarding
a placebo group in a long-term study in COPD patients [12]. The
safety of IND 75 mg q.d. has already been evaluated in 12-week
duration studies, showing an AE rate similar to that of placebo [17].
In this study, GLY was well tolerated over 52 weeks of treatment
with an overall incidence of AEs similar to that of IND. Most of the
reported AEs were of mild to moderate severity, which further
supported the safety of GLY b.i.d. A higher incidence of respiratory-
related AEs as observed in this study is expected for long-term
studies which evaluate safety in COPD population [18]. AE report-
ing rates in the previous GEM studies (referred to as GEM1 and
GEM2) were comparable between glycopyrrolate 15.6 mg b.i.d.
treatment and placebo.
The incidence of SAEs reported in this study was low and
comparable between the treatment groups, with a majority beingrelated to the respiratory, thoracic, and mediastinal disorders sys-
tem organ class in both treatment groups. Moreover, the nature/
type of SAEs seen in this study was similar to that in a one-year
safety study with tiotropium [20]. It should be noted that the as-
sociation of cardiovascular morbidity and mortality in COPD pop-
ulations is well known; thus, CCV events in this study investigating
an elderly patient population were to be expected [21]. The inci-
dence of adjudicated serious CCV AEs, including MACE and non-
MACE outcomes, in GEM3 was comparable between both treat-
ment groups. However, due to the low number of patients with
MACE, caution should be exercised when interpreting results be-
tween the treatment groups. The rate of adjudicated atrial ﬁbril-
lation/ﬂutter events was low and balanced between the treatment
groups (GLY, one patient [0.4%] versus IND, two patients [0.8%]).
Notably, there were no thromboembolic outcomes associated with
the events of atrial ﬁbrillation/ﬂutter events. The incidence of atrial
ﬁbrillation was generally similar to that of other marketed LAMAs
[22,23].
The GEM3 study illustrates the relevant concerns regarding the
cardiovascular safety of LAMAs in general; e.g., cardiovascular
safety concerns which were raised for tiotropium since its launch in
2004 [24]. Those concerns were largely addressed with the results
of the Tiotropium Safety and Performance in Respimat (TIOSPIR)
trial which speciﬁcally included patients with a medical history of
cardiac disorders such as arrhythmias, myocardial infarction, or
cardiac failure, where tiotropium showed an acceptable safety
proﬁle [25]. A comprehensive safety analysis from the GLOW
(GLycopyrronium bromide in COPD airWays) clinical studies
showed that glycopyrronium 50 mg q.d. had an acceptable safety
proﬁle, with low frequencies of cardiac and typical anti-muscarinic
adverse effects [8,10]. Moreover, the SHINE and SPARK studies
showed that glycopyrronium, used in combination with indaca-
terol, did not lead to any associated risks towards the cardiovas-
cular safety, and had a safety proﬁle similar to that of tiotropium, in
patients with COPD [26,27].
Lung function parameters, such as pre-dose trough FEV1, trough
FVC, and the number of exacerbation rates, were evaluated as
secondary objectives. No statistically signiﬁcant and clinically
relevant differences were observed for these parameters between
both treatment groups. At the end of the treatment period, the
change from baseline in pre-dose trough FEV1 was comparable
between the groups. However, a decline in pre-dose trough FEV1
was observed across the treatment groups over time (Fig. 3). This
lung function decline has been reported to be consistent with the
underlying progressive nature of COPD [28]. Due to the lack of a
placebo comparator in this study, the actual treatment effect of GLY
must be interpreted with caution as, without placebo adjustment,
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decline which is expected without treatment [28]. Considering the
fact that the patients selected in this study had no or a very low risk
of exacerbations, the incidences of COPD exacerbations observed
during the treatment period were low, too. Overall, a similar lung
function improvement was achieved with GLY as compared to IND,
an approved bronchodilator in the United States with an estab-
lished efﬁcacy proﬁle.
5. Conclusion
This long-term study shows that GLY 15.6 mg b.i.d. has a favor-
able safety and tolerability proﬁle, similar to that of an approved
LABA, IND 75 mg q.d., in COPD patients. Low incidences of SAEs,
MACE, atrial ﬁbrillation, and deaths indicate that treatment with
GLY 15.6 mg b.i.d. poses a low risk including cardiovascular risk in
COPD patients, comparable to indacaterol. Moreover, treatment
with GLY led to an improvement in lung function over 52 weeks,
which was comparable to that with IND. Overall, the safety and
efﬁcacy results of the GEM3 study show that GLY 15.6 mg b.i.d. is a
treatment option for patients with stable, symptomatic COPD with
moderate-to-severe airﬂow limitation.
Acknowledgments
This study was designed and sponsored by Novartis Pharma AG,
Basel. The authors would like to thank patients and staff at the
participating centers. The authors also thank Novartis clinical team
members Cathy Surdouski, Colleen Spotts, Janet Jenkins, Michael
Kleinhoffer, and Pamalar Lewis for their contributions in executing
the study. The authors thank DataMap GmbH, Novartis designated
CROs for supporting the preparation of the statisticial analyses in
the clinical study report. The authors also thank Parveen Sarkari
and Pravita Balijepalli (professional medical writers; Novartis) for
assistance in the preparation of this manuscript. All authors
participated in the development and writing of the manuscript and
take full responsibility for the content of the article. All authors
approved the ﬁnal draft that was submitted. This study was pub-
lished as an abstract and presented at the CHEST annual meeting
2015, Montreal, Canada, October 24e28, 2015.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.rmed.2016.03.015.
References
[1] National Vital Statistics Report (NVSR). Deaths: Leading causes for 2012. (64).
Available from http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64_10.pdf.
[2] K. Hasegawa, et al., Frequent utilization of the emergency department for
acute exacerbation of chronic obstructive pulmonary disease, Respir. Res. 15
(2014) 40.
[3] Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung
Disease (2015). accessed on 15.09.15. Available from http://www.goldcopd.
org/uploads/users/ﬁles/GOLD_Report_2015.pdf.[4] American Thoracic Society ERS. Standards for the Diagnosis and Management
of Patients with COPD (2004). accessed on 15.09.15. Available from http://
www.thoracic.org.
[5] C. Fogarty, et al., Bronchodilatory effects of NVA237, a once daily long-acting
muscarinic antagonist, in COPD patients, Respir. Med. 105 (3) (2011)
337e342.
[6] C. Verkindre, et al., Sustained 24-h efﬁcacy of NVA237, a once-daily long-
acting muscarinic antagonist, in COPD patients, Respir. Med. 104 (10) (2010)
1482e1489.
[7] European Medicines Agency. Seebri Breezhaler (glycopyrronium bromide:
summary of product characteristics) Available from http://www.ema.europa.
eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/
002430/WC500133769.pdf.
[8] A. D'Urzo, et al., Efﬁcacy and safety of once-daily NVA237 in patients with
moderate-to-severe COPD: the GLOW1 trial, Respir. Res. 12 (2011) 156.
[9] K.R. Chapman, et al., A blinded evaluation of the efﬁcacy and safety of gly-
copyrronium, a once-daily long-acting muscarinic antagonist, versus tio-
tropium, in patients with COPD: the GLOW5 study, BMC Pulm. Med. 14 (2014)
4.
[10] E. Kerwin, et al., Efﬁcacy and safety of NVA237 versus placebo and tiotropium
in patients with COPD: the GLOW2 study, Eur. Respir. J. 40 (5) (2012)
1106e1114.
[11] A.D. D'Urzo, et al., Safety of inhaled glycopyrronium in patients with COPD: a
comprehensive analysis of clinical studies and post-marketing data, Int. J.
Chron. Obstruct. Pulmon. Dis. 10 (2015) 1599e1612.
[12] FDA Draft Guidance for Industry, Chronic Obstructive Pulmonary Disease:
Developing Drugs for Treatment, U.S. Department of Health and Human
Services. Food and Drug Administration. Center for Drug Evaluation and
Research, 2007.
[13] C. LaForce, et al., Efﬁcacy and safety of twice-daily glycopyrrolate in patients
with stable, symptomatic COPD with moderate-to-severe airﬂow limitation:
the GEM1 study, Int. J. Chron. Obstruct. Pulmon. Dis. 11 (2016) (in press).
[14] E. Kerwin, et al., Efﬁcacy and safety of twice-daily glycopyrrolate versus pla-
cebo in patients with COPD: the GEM2 study, Chronic Obstr. Pulm. Dis.
(Miami) 3 (2) (2016) (in press).
[15] FDA Approves New Novartis Dual Combination Bronchodilator Utibron™
Neohaler® for Patients with Chronic Obstructive Pulmonary Disease, October
29, 2015. Available from: http://www.pharma.us.novartis.com/info/
newsroom/news-description.jsp?id¼137236.
[17] E.M. Kerwin, et al., Efﬁcacy and tolerability of indacaterol 75 mg once daily in
patients aged 40 years with chronic obstructive pulmonary disease: results
from 2 double-blind, placebo-controlled 12-week studies, Clin. Ther. 33 (12)
(2011) 1974e1984.
[18] C.R. Jenkins, et al., Efﬁcacy of salmeterol/ﬂuticasone propionate by GOLD stage
of chronic obstructive pulmonary disease: analysis from the randomised,
placebo-controlled TORCH study, Respir. Res. 10 (2009) 59.
[20] R. Casaburi, et al., A long-term evaluation of once-daily inhaled tiotropium in
chronic obstructive pulmonary disease, Eur. Respir. J. 19 (2) (2002) 217e224.
[21] L. Huiart, et al., Cardiovascular morbidity and mortality in COPD, Chest 128 (4)
(2005) 2640e2646.
[22] Boehringer Ingelheim GmbH, SPIRIVA® HandiHaler® (Tiotropium Bromide
Inhalation Powder), 2014. US Prescribing Information. Package insert,
(IT1600AED292014).
[23] L.L.C. GlaxoSmithKline, Incruse™ Ellipta® (Umeclidinium Bromide and
Vilanterol Trifenatate Powder), 2014. US Prescribing Information. Package
insert, (NDC 0173-0873-10).
[24] S. Singh, et al., Inhaled anticholinergics and risk of major adverse cardiovas-
cular events in patients with chronic obstructive pulmonary disease: a sys-
tematic review and meta-analysis, JAMA 300 (12) (2008) 1439e1450.
[25] R.A. Wise, et al., The tiotropium safety and performance in respimat trial
(TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design
and rationale, Respir. Res. 14 (2013) 40.
[26] E.D. Bateman, et al., Dual bronchodilation with QVA149 versus single bron-
chodilator therapy: the SHINE study, Eur. Respir. J. 42 (6) (2013) 1484e1494.
[27] J.A. Wedzicha, et al., Analysis of chronic obstructive pulmonary disease ex-
acerbations with the dual bronchodilator QVA149 compared with glyco-
pyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-
group study, Lancet Respir. Med. 1 (3) (2013) 199e209.
[28] C. Tantucci, et al., Lung function decline in COPD, Int. J. Chron. Obstruct.
Pulmon. Dis. 7 (2012) 95e99.
